7.90
-0.21(-2.59%)
Currency In USD
| Previous Close | 8.11 |
| Open | 8.03 |
| Day High | 8.08 |
| Day Low | 7.89 |
| 52-Week High | 9.48 |
| 52-Week Low | 6.29 |
| Volume | 1.72M |
| Average Volume | 1.88M |
| Market Cap | 3.68B |
| PE | -197.5 |
| EPS | -0.04 |
| Moving Average 50 Days | 7.43 |
| Moving Average 200 Days | 8.14 |
| Change | -0.21 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $526.32 as of June 18, 2025 at a share price of $7.9. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $1,595.96 as of June 18, 2025 at a share price of $7.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
GlobeNewswire Inc.
Jun 12, 2025 12:00 PM GMT
Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announ
Amneal to Participate at Upcoming Investor Conferences in June
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET,
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire Inc.
May 15, 2025 12:00 PM GMT
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J.,